Clinical features of LRP4/agrin-antibody-positive myasthenia gravis: A multicenter study
This article presents a multicenter study aimed at identifying the prevalence and clinical characteristics of LRP4/agrin-antibody-positive, double-seronegative myasthenia gravis (DNMG). The study included 181 DNMG patients who were tested for LRP4 and agrin antibodies. The results showed that 14.9% of DNMG patients were positive for either LRP4 or agrin antibodies, with 12.7% positive for both antibodies. The antibody-positive patients had more severe clinical disease compared to antibody-negative patients. However, most DNMG patients, regardless of antibody status, responded well to standard therapy. The study highlights the prevalence and clinical significance of LRP4 and agrin antibodies in DNMG patients.